Hyperthermic Drug Delivery Systems
Welcome to the Investors section of the Combat Medical website. Below is an introduction to the management team of Combat Medical. Combat has successfully raised investment funding and is currently seeking to close an investment round. To discuss further please contact Edward Bruce-White, CEO on +44 1582 343 120
Combat medical is the world leader in hyperthermic drug delivery systems, with its innovative multi-patented, CE marked systems it provides disruptive technology that enhances drug delivery and improves efficacy and therefore outcomes in the treatment of a range of cancers. Combat currently has two types of system on the market that are actively sold in 40+ countries and have completed over 55k+ treatments to date. Currently our core business is in the field of Bladder and Peritoneal Cancer, however our technology has the ability and growing data to support and develop its use in several other cancer types including but not limited to: Colorectal, Stomach and Ovarian.
In addition to the core business we are working with some of the world’s top medical institutions and pharmaceutical companies to further develop and utilise our technology. It has been confirmed that Combats technologies can enhance activation or provide a catalyst for some of the most exciting new cancer drugs to be developed for decades.
In combination with our cutting-edge technology, it is our priority to make our systems easy to use, affordable and scalable within public healthcare systems globally. Our overreaching aim is to provide effective treatments that be easily integrated into current practice and make a positive change to the lives of the patients receiving those treatments.
Edward Bruce-White – CEO/Co-Founder
With over 17 years of experience specifically in medical device management he was part of the team that led a successful US$330m IPO listing of The Laryngeal Mask Company (LMA) which successfully reformed the anaesthesia market. Following the IPO Edward was Director of Business Development and was successful in acquiring, integrating and selling other medical devices for LMA. A Successful entrepreneur, his background prior to medical devices was in company turnaround, corporate restructure, mergers, acquisitions, accountancy (E&Y) and property development.
Alberto Martinez Albalat – Director of R&D, Founder and Chairman
A qualified pharmacist with a PhD, a Masters in Pharmaceutical marketing and an MBA, he speaks multiple languages, has founded, commercialised and sold several businesses, has invented and patented several products and has over 22 years’ experience in getting innovative medical products to market. A successful entrepreneur with a strong pharmaceutical and business background.
Adicil mincias pediand aectem ant et am que pelecti te nusamus et quae que reroreptibus molorum esequibust accatus et omnis ea int endam rem volest volupti Adicil mincias pediand aectem ant et am que pelecti te nusamus et quae que reroreptibus molorum esequibust accatus et omnis ea int endam rem volest volupti.
Ronnie Potel – Non-Executive Director
Co-Founder of Radian Partners, a progressive investment community focusing on sustainability, innovation and creativity. Ronnie is a trained barrister in the UK. Formerly an investment banker in the Asia Pacific capital markets with senior regional and global roles at Deutsche Bank, Citibank, Standard Chartered and Morgan Stanley. Ronnie has raised over US$25 billion for corporates globally across sectors and stages of business. Ronnie has spent 15 years in Asia-Pacific, actively transacting during that period all over the far East from India through to Australia.
Andrea Mica – Oxford Technology Management – Lead UK Investor
Founded in 1983 with 30 years science investment in and around Oxford. Runs 4 Venture Capital Trusts and the Oxford Technology Seed Enterprise Investment Scheme. 40 companies invested via VCT and 23 companies invested via EIS. UK’s Longest established specialist start-up investor. Partners: Lucius Care OBE and Andrea Mica.